Results 181 to 190 of about 3,125,328 (279)

The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer

, 2016
Mei‐Ren Pan, Ming‐Chuan Hsu, Chi‐Wen Luo, Li‐Tzong Chen, Yan‐Shen Shan, Wen-Chun Hung   +5 more
openalex   +2 more sources

Harnessing Next‐Generation 3D Cancer Models to Elucidate Tumor‐Microbiome Crosstalk

Advanced Healthcare Materials, Volume 15, Issue 1, 9 January 2026.
Centralizes the microbiome within 3D tumor‐microbiome model platforms, including spheroids, organoids, 3D‐bioprinted constructs, and microfluidic chips, each enabling structured host‐tumor‐microbe studies. These systems support bacterial colonization, facilitating investigation of microbial impacts on tumor growth, immunity, and therapy. The microbiome
Marina Green Buzhor, Giuseppe Longobardi, Or Kandli, Anne Krinsky, Opal Avramoff, Anshika Katyal, Koren Salomon, Adan Miari, Dana Venkert, Tania T. Barnatan, América García Alvarado, Shahar Greenberg, Ronit Satchi‐Fainaro   +12 more
wiley   +1 more source

TPI1 enhances gemcitabine resistance in bladder cancer by promoting autophagy through activating Beclin-1. [PDF]

Cell Death Dis
Wang C, Li K, Wan S, Chen S, Liu S, Yang L.   +5 more
europepmc   +1 more source

Supplementary Data from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance

Suman Dash, Takeshi Ueda, Akiyoshi Komuro, H. Amano, Masahiko Honda, Masahito Kawazu, Hitoshi Okada   +6 more
openalex   +1 more source

Probiotic‐Based Materials as Living Therapeutics

Advanced Materials, Volume 38, Issue 1, 2 January 2026.
Recent advances in Engineered Living Materials are highlighted, integrating synthetic biology and advanced materials, with a focus on probiotic‐based therapeutics. Probiotic Living Materials hold great potential for biosensing, infection treatment, osteogenesis, wound healing, vaginal and gastrointestinal disorders, and cancer therapy. breakthroughs in
Laura Sabio, Graham J. Day, Manuel Salmeron‐Sanchez   +2 more
wiley   +1 more source

SLC6A14-mediated glutamine promotes SYTL4-CXCL8 axis activation to drive gemcitabine resistance and immune evasion in pancreatic cancer. [PDF]

Exp Mol Med
Kang HW, Kim JH, Jeong JW, Fang S, Yun WG, Jung HS, Kwon W, Jang JY, Kim HJ, Park JS.   +9 more
europepmc   +1 more source

Peer Review #3 of "GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer (v0.1)"

, 2022

openalex   +1 more source

Tumor‐Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells

Advanced Science, Volume 13, Issue 5, 27 January 2026.
This study demonstrates that tumor‐derived IL‐35 promotes pancreatic cancer fibrosis by indirectly activating pancreatic stellate cells through IGFBP2/IGF‐1R/PI3K‐Akt and Tsp‐1/TGF‐β pathways. IL‐35 blockade reduces stromal fibrosis, restores chemosensitivity, and synergizes with gemcitabine‐based regimens, highlighting IL‐35 as a promising therapeutic
Hui Li, Huizhi Sun, Jing Liu, Yan Wu, Lin Wei, Jianming Li, Yudong Yuan, Peng Xie, Chao Xu, Guolu Luo, Yuqi Guan, Yukuan Feng, Antao Chang, Jihui Hao, Chongbiao Huang   +14 more
wiley   +1 more source

A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer

Advanced Science, Volume 13, Issue 4, 19 January 2026.
LZU‐WZLYCS01 is a novel FGFR3‐targeting ADC for bladder cancer with 7‐ethyl‐9‐fluorocamptothecin (A2) as its cytotoxic payload. LZU‐WZLYCS01 intracellularly releases A2, which targets MAD2L1 to activate the cGAS‐STING pathway and induce tumor cell apoptosis.
Shu Cui, Xiongfei Luo, Guangrui Fan, Jingqi Jiang, Yingru Wang, Enguang Yang, Jinpeng Ma, Ze Zhang, Yuhan Wang, Juan Wang, Dengtuo Wang, Hanzhang Wang, Liang Cheng, Junqiang Tian, Zhilong Dong, Yingqian Liu, Zhiping Wang   +16 more
wiley   +1 more source

Role and molecular mechanisms of hypoxia-derived exosomal miR-301a on gemcitabine resistance in pancreatic cancer. [PDF]

Oncol Lett
Qu W, Tan W, Ye M, Tang W, Zhang L, Luo G.   +5 more
europepmc   +1 more source